European Growth Companies With High Insider Ownership For May 2025

8 hours ago 15

editorial-team@simplywallst.com (Simply Wall St)

Wed, May 14, 2025, 10:37 PM 4 min read

In This Article:

As of May 2025, European markets person shown resilience, with the pan-European STOXX Europe 600 Index rising for a 4th consecutive week amid optimism implicit easing commercialized tensions betwixt China and the U.S. This affirmative sentiment is further buoyed by Germany's robust concern output and caller monetary argumentation adjustments crossed respective European countries. In specified an environment, maturation companies with precocious insider ownership tin beryllium peculiarly appealing to investors seeking alignment betwixt absorption interests and shareholder value, arsenic these traits whitethorn bespeak assurance successful the company's aboriginal prospects amidst evolving marketplace dynamics.

Name

Insider Ownership

Earnings Growth

Pharma Mar (BME:PHM)

11.8%

43.1%

KebNi (OM:KEBNI B)

38.3%

66.1%

Yubico (OM:YUBICO)

36.5%

30.4%

Bergen Carbon Solutions (OB:BCS)

12%

63.2%

Vow (OB:VOW)

13.1%

81%

Elicera Therapeutics (OM:ELIC)

23.8%

97.2%

CD Projekt (WSE:CDR)

29.7%

37.4%

Elliptic Laboratories (OB:ELABS)

22.6%

51.9%

Norbit (OB:NORBT)

13.2%

26.6%

Nordic Halibut (OB:NOHAL)

29.7%

60.7%

Click present to spot the afloat database of 209 stocks from our Fast Growing European Companies With High Insider Ownership screener.

We'll analyse a enactment from our screener results.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ambu A/S is simply a aesculapian exertion institution that develops, produces, and sells aesculapian devices to hospitals, clinics, and rescue services globally, with a marketplace headdress of DKK27.81 billion.

Operations: The company's gross is derived from Disposable Medical Products, amounting to DKK5.83 billion.

Insider Ownership: 24.9%

Earnings Growth Forecast: 24.8% p.a.

Ambu A/S demonstrates beardown maturation prospects with net forecasted to summation by 24.8% annually, outpacing the Danish market's 7.7%. Recent fiscal results amusement robust performance, with second-quarter income rising to DKK 1.55 cardinal and nett income reaching DKK 188 million. Despite trading astatine a discount of 17.6% beneath its estimated just value, Ambu's gross is expected to turn astatine a complaint of 10.2%, surpassing the broader market's gait of 8.2%.

AMBU B Earnings and Revenue Growth arsenic  astatine  May 2025

CPSE:AMBU B Earnings and Revenue Growth arsenic astatine May 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Surgical Science Sweden AB (publ) specializes successful processing and selling virtual world simulators for evidence-based aesculapian grooming globally, with a marketplace headdress of SEK7.69 billion.

Operations: The company's gross is derived from 2 main segments: Industry/OEM, contributing SEK441.59 million, and Educational Products, accounting for SEK442.50 million.

Read Entire Article